Aytu BioPharma, Inc. (AYTU)

Aytu Biopharma's stock (AYTU) has experienced an upward trend, increasing by 20.19% in the past six months and 103.25% over the past year. Key events impacting the stock price include reporting its first-ever positive net income from continuing operations in Q1 Fiscal Year 2025, reporting Q2 Fiscal Year 2026 earnings, holding an Analyst/Investor Day, revisions to consensus EPS and revenue estimates, and rewriting warrant terms to restore equity.

Specific month-by-month demand seasonality for Aytu Biopharma's products is not explicitly detailed, but the ADHD market and fluoride supplements have shown increasing trends. Persistent stimulant shortages and supply disruptions in the ADHD market have allowed Aytu's products to fill a significant void and drive growth. The company's stock performance has shown some monthly seasonality, with December historically having the highest probability of positive returns and August the lowest.

Aytu Biopharma, Inc. is a specialty pharmaceutical company focused on advancing innovative medicines for complex central nervous system (CNS) diseases, particularly major depressive disorder (MDD) and attention deficit hyperactivity disorder (ADHD), and has a significant pediatric portfolio. Its major commercialized products include ADHD medications like Adzenys XR-ODT and Cotempla XR-ODT, pediatric products such as Karbinal ER and Poly-Vi-Flor, and the MDD product EXXUA. Aytu also has a therapeutic development pipeline, including AR101/enzastaurin, a prospective treatment for vascular Ehlers-Danlos Syndrome.

Aytu Biopharma operates primarily in the United States and is headquartered in Denver, Colorado. The company is expanding its distribution into select international ophthalmic and specialty markets, particularly in Europe and the Middle East, leveraging the commercial infrastructure gained from its 2024 merger with Alimera Sciences. Aytu has also out-licensed its ADHD brands for commercialization in Israel, the Palestinian Authority, and Canada.

Aytu BioPharma aims to advance innovative medicines for complex CNS diseases. However, in September 2025, the FDA issued warning letters to Aytu Biopharma because sponsored links for its ADHD drugs, Cotempla XR-ODT and Adzenys XR-ODT, were false or misleading, creating a misleading impression about the safety and efficacy of these Schedule II controlled substances.

Aytu BioPharma has 39 institutional owners and shareholders, holding a total of 3,718,605 shares. Major institutional shareholders include Nantahala Capital Management, LLC, Stonepine Capital Management, LLC, and AWM Investment Company, Inc. As of late 2025, institutional investors collectively held approximately 28.5% of outstanding common stock, while retail investors retained roughly 65% of the float. The founders' stake has been diluted over time due to acquisition-driven growth financed largely through equity issuance.